| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.41 | 2e-40 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.33 | 3e-26 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.3 | 6e-23 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.41 | 2e-21 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.26 | 6e-16 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.29 | 3e-09 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-08 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.28 | 2e-08 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-08 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.22 | 9e-07 |